JPM

305.36

+0.03%↑

BAC

52.58

-0.45%↓

WFC

86.03

-0.92%↓

MS

163.85

-0.76%↓

AXP

357.96

-0.99%↓

JPM

305.36

+0.03%↑

BAC

52.58

-0.45%↓

WFC

86.03

-0.92%↓

MS

163.85

-0.76%↓

AXP

357.96

-0.99%↓

JPM

305.36

+0.03%↑

BAC

52.58

-0.45%↓

WFC

86.03

-0.92%↓

MS

163.85

-0.76%↓

AXP

357.96

-0.99%↓

JPM

305.36

+0.03%↑

BAC

52.58

-0.45%↓

WFC

86.03

-0.92%↓

MS

163.85

-0.76%↓

AXP

357.96

-0.99%↓

JPM

305.36

+0.03%↑

BAC

52.58

-0.45%↓

WFC

86.03

-0.92%↓

MS

163.85

-0.76%↓

AXP

357.96

-0.99%↓

Search

Fidus Investment Corp

Gesloten

20.63 -1.86

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

20.53

Max

21.03

Belangrijke statistieken

By Trading Economics

Inkomsten

5.6M

25M

Verkoop

-4.1M

32M

K/W

Sectorgemiddelde

9.1

27.54

Dividendrendement

8.35

Winstmarge

78.032

EBITDA

7.6M

33M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+3.46% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

8.35%

3.88%

Volgende Winsten

30 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

20M

741M

Vorige openingsprijs

22.49

Vorige sluitingsprijs

20.63

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Fidus Investment Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 okt 2025, 23:50 UTC

Populaire aandelen

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 okt 2025, 23:25 UTC

Winsten

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 okt 2025, 23:18 UTC

Winsten

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 okt 2025, 22:20 UTC

Winsten

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 okt 2025, 22:13 UTC

Winsten

Wal-Mart de Mexico Net Profit Falls in 3Q

28 okt 2025, 21:38 UTC

Winsten

Correction to Visa Sales Jump Article

28 okt 2025, 21:17 UTC

Winsten

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 okt 2025, 21:07 UTC

Winsten

Visa Sales Jump as Consumers Keep Spending -- Update

28 okt 2025, 21:02 UTC

Winsten

Mondelez Tempers Outlook as Costs Rise

28 okt 2025, 23:51 UTC

Marktinformatie

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 okt 2025, 23:42 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 okt 2025, 23:02 UTC

Winsten

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 okt 2025, 23:01 UTC

Winsten

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 okt 2025, 22:46 UTC

Winsten

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 okt 2025, 22:45 UTC

Winsten

SK Hynix 3Q Net KRW12.6T >000660.SE

28 okt 2025, 22:44 UTC

Winsten

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 okt 2025, 22:43 UTC

Winsten

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 okt 2025, 22:42 UTC

Winsten

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 okt 2025, 22:40 UTC

Winsten

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 okt 2025, 22:40 UTC

Winsten

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 okt 2025, 22:22 UTC

Winsten

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 okt 2025, 22:20 UTC

Winsten

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 okt 2025, 22:02 UTC

Winsten

Review & Preview: Earnings Extravaganza -- Barrons.com

28 okt 2025, 21:42 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

28 okt 2025, 21:42 UTC

Marktinformatie
Winsten

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 okt 2025, 21:20 UTC

Winsten

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 okt 2025, 21:19 UTC

Winsten

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 okt 2025, 21:18 UTC

Winsten

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Vergelijking

Prijswijziging

Fidus Investment Corp Prognose

Koersdoel

By TipRanks

3.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 21.8 USD  3.46%

Hoogste 22.5 USD

Laagste 21 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fidus Investment Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Technische score

By Trading Central

19 / 19.0999Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Fidus Investment Corp

Fidus Investment Corporation is a business development company. It specializing in leveraged buyouts, refinancings, change of ownership transactions, recapitalizations, strategic acquisitions, mezzanine, growth capital, business expansion, lower middle market investments, debt investments, subordinated and second lien loans, senior secured and unitranche debt, preferred equity, warrants, subordinated debt, senior subordinated notes, junior secured loans, and unitranche loans. It does not invest in turnarounds or distressed situations. The fund prefers to invest in aerospace and defense, business services, consumer products and services including retail, food, and beverage, healthcare products and services, industrial products and services, information technology services, niche manufacturing, transportation and logistics, and value-added distribution sectors. It seeks to invest in companies based in United States. The fund typically invests between $5 million and $15 million per transaction in companies with annual revenues between $10 million and $150 million and an annual EBITDA between $3 million and $20 million, but it can occasionally invest in larger or smaller companies. It seeks to acquire minority equity stakes and board observation rights in conjunction with its investments.
help-icon Live chat